The gene therapy market is projected to grow at a CAGR of 40.8% in the first half of the forecast period. In 2016, the cancer treatment submarket accounted for 75.0% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the second half of the forecast period.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand-new 127 page report you will receive 70 charts – all unavailable elsewhere.
The 127-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Gene Therapy market forecasts from 2017-2027
• This report assesses the approved gene therapy products in the market and gives revenue to 2027 for Neovasculgen
• Provides qualitative analysis and forecast of the submarket by indication for the period 2017-2027:
• Cancer
• Cardiovascular disorders
• Rare diseases
• Ophthalmological diseases
• Other therapeutic uses
• Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
• UniQure
• Biogen
• Bluebird Bio
• Spark Therapeutics
• Applied Genetics Technologies Corporation
• Oxford Biomedica
• GenSight Biologics
• Assesses the outlook for the leading gene treatment R&D pipeline for 2016 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for six leading agents:
• SPK-RPE65 (Spark Therapeutics)
• Collategene (AMG0001, AnGes MG/Vical)
• Invossa (TissueGene-C, TissueGene Inc/Kolon Life Science)
• BC-819 (BioCancell)
• Lenti-D (Bluebird Bio)
• GSK2696273 (GlaxoSmithKline)
• Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2017 to 2027. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.
• Our study discusses factors that influence the market including these:
• Translation of research into marketable products modifying human DNA – gene transfer for therapeutic use, altering the nuclear genome
• Genomic editing technology and other supporting components
• Collaborations to develop and launch gene-based products – acquisitions and licensing deals
• Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
• Gene therapies for ophthalmologic diseases – next-generation medicines
• Regulations in the United States, the European Union and Japan – overcoming technological and medical challenges to pass clinical trials.
Visiongain’s study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.
Buy our report today Gene Therapy R&D market Analysis : Cancer, Cardiovascular, Rare Diseases, Ophthalmologic, Other Diseases.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Gene Therapy Market Overview
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Gene Therapy
2.1 What is Gene Therapy?
2.2 Types of Gene Therapy
2.3 Products Excluded from the Report
2.4 Gene Therapy Vectors
3. Gene Therapy World Market: Leading Treatments and Forecasts, 2016-2027
3.1 The World Market for Gene Therapy: Overview of Products
3.2 Gendicine (rAd-p53) – The First Gene Therapy to Market
3.3 Oncorine: Growth is Hindered by Certain Factors
3.4 Neovasculgen: Russia’s First Gene Therapy
3.4.1 Neovasculgen: Historical Performance and Revenue Forecast, 2016-2027
3.5 Glybera: A Drug with Promise
3.5.1 Glybera: Pricing Ends the Dream to Become a Blockbuster Product
4. Gene Therapy World Market and Disease Submarkets, 2016-2027
4.1 The Global Market for Gene Therapy Drug Treatments in 2016
4.2 Gene Therapy Market Forecast, 2016-2027
4.3 Gene Therapy for Cancer
4.3.1 Clinical Trials for Cancer
4.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2016-2027
4.4 Gene Therapy for Rare Diseases
4.4.1 The Rare Disease Treatment Submarket Forecast 2016-2027
4.5 Gene Therapy for Cardiovascular Diseases
4.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2016-2027
4.6 Gene Therapy for Ophthalmologic Diseases
4.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases
4.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2016-2027
4.7 Gene Therapy for Other Diseases
4.7.1 The Other Disease Treatment Submarket Forecast 2016-2027
4.8 Changing Market Shares: Cancer Disease Gene Therapies Will Dominate and Become Market Leader
5. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future
5.1 UniQure- the First Commercial Stage Gene Therapy Company in the West
5.2 Biogen - Focusing on Ophthalmologic and Rare Disease Gene Therapies
5.3 Bluebird Bio: Gene Editing Technology
5.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US
5.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases
5.6 Oxford Biomedica: Collaboration as a Strategy
5.7 GenSight Biologics - Novel Mitochondrial Technology Platform
5.8 Gene Therapy and Big Pharma: Collaborations
6. R&D Pipeline Analysis and Forecasts, 2016-2027
6.1 Pipeline
6.2 Pipeline Analysis
6.3 GSK2696273 – GSK
6.4 Collategene (AMG0001) - AnGes MG/Vical
6.5 BC-819 - BioCancell
6.6 BC-821 - BioCancell
6.7 Lenti-D - Bluebird Bio
6.8 LentiGlobin (LentiGlobin BB305) - Bluebird Bio
6.9 SPK-RPE65 - Spark Therapeutics
6.10 SPK-CHM - Spark Therapeutics
6.11 SPK-FIX - Spark Therapeutics/Pfizer
6.12 SPK-TPP1- Spark Therapeutics
6.13 Invossa (TissueGene-C) - TissueGene Inc/Kolon Life Science
6.14 VM202-DPN - ViroMed
6.15 Important Pipeline Technology Developments
6.16 The Future of the Gene Therapy Pipeline
7. Qualitative Analysis of the Gene Therapy Market, 2017-2027
7.1 SWOT Analysis of the Gene Therapy Treatment Market, 2017
7.2 Strengths: A Vast Pipeline for a Wide Range of Indications
7.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth
7.4 Opportunities and Threats for the Gene Therapy Drug Market, 2017-2027
7.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way
7.6 Threats: Expensive Drugs with Strict Regulations
7.7 National Markets: Regulation of the Gene Therapy Market
7.7.1 Gene Therapy Regulations: Evolving with the Market
7.7.2 US Regulations: Strict Regulation of a Cautious Market
7.7.3 EU Regulations: One Approval So Far
7.7.4 Japanese Regulations: A Rigorous Process
8. Conclusions
8.1 The World Gene Therapy Treatment Market: Current World Outlook
8.1.1 Leading Gene Therapy Treatment Submarkets and Products, 2016-2027
8.1.2 Driver for Growth to 2027: A Vast Pipeline of Gene Therapy Products
8.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success
8.2 The Future of the Gene Therapy Treatment Market
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 1.1 Foreign Currency Exchange Rates Utilised: Exchange Rate to $US, 2015, 2016, and 2017
Table 3.1 Approved Gene Therapies, 2016
Table 3.2 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2013-2016
Table 3.3 Neovasculgen Forecast, Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.1 Leading Gene Therapy Drugs by Revenue ($m), 2016
Table 4.2 World Market Forecasts for Gene Therapy Drugs by Indication, Market Sizes ($m), Annual Growth Rates (%), CAGR (%), 2016-2027
Table 4.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2016
Table 4.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2016
Table 4.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2016
Table 4.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2016
Table 4.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2016
Table 4.8 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2016
Table 4.9 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2016
Table 4.10 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2016
Table 4.11 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 4.12 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2017
Table 4.13 Rare Diseases Gene Therapy Pipeline, 2016
Table 4.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 4.15 Cardiovascular Gene Therapy Pipeline, 2016
Table 4.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 4.17 Preclinical Ophthalmologic Pipeline, 2016
Table 4.18 Clinical Ophthalmologic Pipeline, 2016
Table 4.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2016
Table 4.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 4.21 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 4.22 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2016-2021
Table 4.23 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2022-2027
Table 5.1 uniQure Pipeline, 2016
Table 5.2 Spark Therapeutics Collaborations, 2016
Table 5.3 Selected Big Pharma Collaborations in Gene Therapy, 2016
Table 6.1 Promising Gene Therapies in Development, 2016
Table 6.2 Gene Therapies in Phase 3, 2016
Table 6.3 GSK2696273 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 6.4 Collategene Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 6.5 BC-819 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 6.6 Lenti-D Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 6.7 SPK-RPE65 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 6.8 Invossa Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 7.1 Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2017
Table 7.2 Gene Therapy Pipeline for Neurodegenerative Diseases, 2016
Table 7.3 Gene Therapy Pipeline for Metabolic Diseases, 2016
Table 7.4 Gene Therapy Pipeline for Musculoskeletal Diseases, 2016
Table 7.5 Gene Therapy Pipeline for Viral Diseases, 2016
Table 7.6 Opportunities and Threats of the Gene Therapy Drug Market, 2017
Table 7.7 Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2016
Table 8.1 Global Gene Therapy Drug Market Forecasts by Indication: Market Size ($m), Market Share (%), CAGR (%), 2016, 2021 and 2027
List of Figures
Figure 1.1 Global Gene Therapy Treatment Market Segmentation Overview, 2016
Figure 2.1 Vectors Used in Gene Therapy Clinical Trials, 2016
Figure 3.1 Neovasculgen Forecast, Revenue ($m), 2016-2027
Figure 4.1 Gene Therapy World Market Forecast, Market Size ($m), AGR (%), 2016-2027
Figure 4.2 Cancer Gene Therapy Pipeline by Phase of Development, 2016
Figure 4.3 Global Gene Therapy Market: Market Shares (%) by Indication, 2016
Figure 4.4 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), 2016-2027
Figure 4.5 Global Gene Therapy Market: Market Shares (%) by Indication, 2017
Figure 4.6 Rare Diseases Gene Therapy Pipeline by Phase of Development, 2016
Figure 4.7 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), 2016-2027
Figure 4.8 Cardiovascular Gene Therapy Pipeline by Phase of Development, 2016
Figure 4.9 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), 2016-2027
Figure 4.10 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), 2016-2027
Figure 4.11 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), 2016-2027
Figure 4.12 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2021
Figure 4.13 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2027
Figure 6.1 Gene Therapies in Clinical Development by Phase, 2016
Figure 6.2 GSK2696273 Forecast, Revenue ($m), 2016-2027
Figure 6.3 Collategene Forecast, Revenue ($m), 2016-2027
Figure 6.4 BC-819 Forecast, Revenue ($m), 2016-2027
Figure 6.5 Lenti-D Forecast, Revenue ($m), 2016-2027
Figure 6.6 SPK-RPE65 Forecast, Revenue ($m), 2016-2027
Figure 6.7 Invossa Forecast, Revenue ($m), 2016-2027
Figure 8.1 Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($m), 2016, 2021, and 2027
4DMT (4D Molecular Therapeutics)
Abeona
AGTC (Applied Genetics Technologies Corporation)
AMT (Amsterdam Molecular Therapeutics)
AnGes MG
Asklepios BioPharma
AstraZeneca
Audentes Therapeutics
Avalanche Biotech
Bayer Healthcare
Beijing Northland Biotech Co
Benda Pharmaceutical
Benitec Biopharma
BioCancell
Biogen
Biogen Idec
Bluebird Bio
BMS (Bristol-Myers Squibb)
Broad Institute/Whitehead Institute
Celgene
Cell Therapy Catapult
Cellectis
Chiesi Farmaceutici
Clearside Biomedical
Convergence Pharmaceuticals
Daiichi Sankyo
Dimension Therapeutics
Editas Medicine
Fondazione Telethon
Francis Crick Institute
Genable Technologies Ltd
Genethon
GenSight Biologics
GenVec
Google
GSK (GlaxoSmithKline)
Henry Ford Health System
HSCI (Human Stem Cells Institute)
HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy),
ImaginAb
Immune Design Corp
InoCard
Inovio
Intellia Therapeutics
Invetech
Kite Pharma
Kolon Group
Kolon Life Science
Lysogene
Mitsubishi Tanabe Pharma Corporation
Neuralgene
NightstaRx
Northwestern Memorial Hospital
Novartis
OXB (Oxford Biomedica)
Pfizer
PNP Therapeutics
Precision Genome Engineering Inc aka Pregenen
ProNai
Protek Group
Raffaele Hospital
REGENX Biosciences
Renova Therapeutics
Roche
Roszdravnadzor
Sangamo Biosciences
Sanofi
Sarepta Therapeutics
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
Sotex Pharm Firm
Spark Therapeutics
SynerGene Therapeutics
Takara Bio
TAP Biosystems
Thermo Fisher Scientific
TissueGene
ToolGen
UC Berkeley
UC San Francisco
uniQure
US Business Innovation Network
Vertex Pharmaceuticals
Vical Incorporated
ViroMed
VM Biopharma
Voyage Therapeutics
Organizations Mentioned in the Report
ASCO (American Society of Clinical Oncology)
ASI (Agency for Strategic Initiatives)
CAT (Committee for Advanced Therapies)
CBER (Center for Biologics Evaluation and Research)
CHMP (Committee for Medicinal Products for Human Use)
CHOP (The Children’s Hospital of Philadelphia)
DCGI (Drugs Controller General of India)
DHHS (Department of Health and Human Services)
EMA (European Medicines Agency)
FDA (US Food and Drug Administration)
INSERM (Institut National de la Santé et de la Recherche Médicale)
IRB (Institutional Review Boards)
MFDS (Korean Ministry of Food and Drug Safety)
MHLW (Ministry of Health, Labour, and Welfare)
MHRA (Medicines and Healthcare Products Regulatory Agency)
Ministry of Health Commission
NHS (National Health Service)
NICE (the National Institute for Health and Care Excellence)
NIH (National Institutes of Health)
OHRP (Office for Human Research Protections)
PMDA (Pharmaceuticals and Medical Devices Agency)
RCGM (Review Committee of Genetic Manipulation)
Russian Ministry of Healthcare and Social Development
SFDA (State Food and Drug Administration of China)
SMC (Scottish Medicines Consortium)
The Fund for Promotion of Small Innovative Enterprises in Science and Technology
The IGI (Innovative Genomics Initiative)
The Innovative Genomics Initiative
The Walter and Eliza Hall Institute
The Wellcome Trust Sanger Institute
WFH (World Federation of Hemophilia)
WHO (World Health Organization)
